TY  - JOUR
AU  - Ferguson, Murdo
AU  - Schwarz, Tino F
AU  - Núñez, Sebastián A
AU  - Rodriguez-Garcia, Juan
AU  - Mital, Marek
AU  - Zala, Carlos
AU  - Schmitt, Bernhard
AU  - Toursarkissian, Nicole
AU  - Mazarro, Dolores Ochoa
AU  - Großkopf, Josef
AU  - Voors-Pette, Christine
AU  - Mehta, Hemalini
AU  - Hailemariam, Hiwot Amare
AU  - de Heusch, Magali
AU  - Salaun, Bruno
AU  - Damaso, Silvia
AU  - David, Marie-Pierre
AU  - Descamps, Dominique
AU  - Hill, Judith
AU  - Vandermeulen, Corinne
AU  - Hulstrøm, Veronica
PY  - 2024
DO  - 10.1093/cid/ciae364
UR  - https://hdl.handle.net/20.500.13003/20943
T2  - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
AB  - The adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVPreF3 OA) is approved in adults aged ≥60 years. We evaluated RSVPreF3 OA immunogenicity and safety in adults aged 50-59 years without or with increased risk for RSV...
LA  - eng
PB  - Oxford
TI  - Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age
TY  - research article
ER  -